On Saturday, two pharmaceutical companies, Danco Laboratories and GenBioPro, approached the Supreme Court to request an intervention to halt a ruling by the 5th U.S. Circuit Court of Appeals. This decision, made just one day prior, significantly impacts the distribution of mifepristone, a widely utilized abortion pill, by eliminating mail-order access. This development marks one of the most significant changes in U.S. abortion policy since the reversal of Roe v. Wade.
Danco Laboratories and GenBioPro, the latter of which manufactures a generic form of mifepristone, sought an emergency stay from the Supreme Court, citing that the appellate court’s decision introduces “immediate confusion and upheaval into highly time-sensitive medical decisions.”
The appeals court in New Orleans unanimously ruled that mifepristone must be dispensed only in person and at clinics, overturning the existing Food and Drug Administration (FDA) regulations, a move seen as a victory by those opposing abortion pills prescribed online.
Mary Ziegler, a University of California at Davis School of Law professor and an expert on abortion law, commented, “We’re now going to see, I think in a way we haven’t before, what the nation will look like when abortion bans are actually in effect.”
Implications Beyond States with Abortion Restrictions
Frustrated with the federal stance on medicated abortions, Louisiana Attorney General Liz Murrill previously filed a lawsuit against the FDA, arguing that allowing mifepristone by mail undermines the state’s total abortion ban. The recent ruling from the appellate court applies nationwide, affecting even states without abortion restrictions.
Josh Thorburn, owner of Eddie’s Pharmacy in Los Angeles, expressed concern, stating, “This is a huge access issue for patients that haven’t got providers close by, or providers close by who are willing to prescribe.”
The incidence of a federal court overruling FDA’s scientific guidelines is rare, raising questions about the long-term impact on abortion access. Murrill celebrated the decision as a “victory for life,” aligning with other anti-abortion advocates who opposed rules established under President Joe Biden that eliminated the need for in-person visits to obtain the pills.
The FDA and the U.S. Department of Justice have yet to comment on the appellate court’s decision.
Mifepristone: A History of Safety and Effectiveness
Approved in 2000, mifepristone is recognized as a safe and effective way to terminate early pregnancies, often used in tandem with misoprostol. While misoprostol remains unaffected by the ruling, it’s less effective when used alone.
Surveys indicate that medication abortions constitute the majority of U.S. abortions, with one in four being prescribed via telehealth. This accessibility is a reason why the number of abortions hasn’t significantly dropped since the overturning of Roe. Consequently, there is heightened focus on targeting abortion pills and their out-of-state prescribers.
In response, some states, led by Democrats, have enacted “shield laws” to protect telehealth providers who mail pills to states with bans. However, these laws face challenges in places like Louisiana and Texas.
In a state with such a shield law, Dr. Angel Foster of The Massachusetts Medication Abortion Project is collaborating with legal experts to assess the ruling’s impact. “We will do everything in our power to continue providing care to people in all 50 states,” she affirmed.
Mini Timmaraju, president and CEO of Reproductive Freedom for All, acknowledged the uncertainty, noting that providers might shift to using just misoprostol for abortion care. “It’s got a chilling effect on providers across the country, and it’s going to have a chilling effect on patients,” she noted.
Potential Influence on Midterm Elections
The case could influence upcoming midterm elections, with Democrats striving to regain the House and Republicans defending their majority. As Ziegler remarked, “This is going to be a pretty significant change in terms of how people experience abortion access, probably as significant as anything we’ve seen since Roe was overturned.”
Recent elections indicate that voters favoring abortion access have gained momentum. Since Roe’s reversal, abortion has been a ballot issue in 17 states, with pro-abortion rights outcomes in 14 instances.
Fatima Goss Graves, president and CEO of the National Women’s Law Center, criticized the ruling as “deeply out of step with both the public and fact-based science.” Ziegler added that the case positions the president to take a more active role on this issue.
Former President Trump faced criticism from anti-abortion advocates for not acting to block pill distribution during his tenure. The FDA under Trump approved another mifepristone generic, displeasing some allies. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, stated, “It’s shameful that the Trump administration’s inaction has forced pro-life states to take their battle to the federal courts,” while applauding the latest appellate ruling.
